Sanofi licenses next-gen radioligand cancer treatment tech from RadioMedix and Orano Med.
Sanofi has entered a licensing agreement with RadioMedix and Orano Med to develop a next-generation radioligand medicine aimed at treating rare cancers. This collaboration seeks to advance innovative treatment options for patients facing these challenging conditions.
September 12, 2024
7 Articles